In hypertension, in addition to the existing therapy, targeting the Ang II-Gal-3-IL6 axis or the mast cell-IL4 axis using Gal-3 inhibitors or IL4 inhibitors could specifically reduce cardiac fibrosis [63, 118••, 119]. This evidence concerns the gene LGALS3 and Hypertension.